Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Scopoletin is a naturally occurring coumarin derivative found in various nootropic herbs, such as *Convolvulus pluricaulis* and *Evolvulus alsinoides*. It acts as a potent antioxidant and neuroprotective agent, particularly studied for its potential in managing Parkinson's disease. Its primary mechanism involves maintaining cellular redox homeostasis by enhancing the levels of reduced glutathione (GSH). This is achieved through the efficient recycling of oxidized glutathione (GSSG) and the inhibition of gamma-glutamyl transpeptidase (GGT), an enzyme responsible for glutathione catabolism. In preclinical models, scopoletin has demonstrated the ability to protect dopaminergic neurons from oxidative stress, restore mitochondrial function, and improve motor coordination. Additionally, it has been shown to alleviate the long-term oxidative toxicity associated with L-DOPA therapy, suggesting potential as a combinatorial treatment to enhance the efficacy of dopamine recharging regimens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on scopoletin.